The ConcertAI Podcast

Jeff Elton sits down with Dr. Robert Miller, Chief Medical and Science Officer at CancerLinQ, to unpack the integration of real-world data and AI in oncology care. Dr. Miller shares his journey from community practice to shaping CancerLinQ, revealing insights into the network's growth and its pivotal role in improving patient care. The episode delves into the transformation of quality measures, the burgeoning role of electronic health records, and the automation of data to enhance the quality and reach of oncological care. As CancerLinQ evolves, discover its expanding capabilities, the drive towards patient-centric care, and the influence on CancerLinQ's partnerships, particularly with ASCO. This is a must-listen for professionals seeking to understand the landscape of data-driven healthcare improvements. Tune in to explore the trajectory of oncology practice transformation with two industry leaders at the helm. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

Jeff Elton, CEO of ConcertAI, and George Sledge, CMO of Caris Life Sciences, embark on an insightful journey through the advancements in oncology. They explore the transformative power of molecular diagnostic testing and how comprehensive data sets are revolutionizing personalized medicine. Delving into topics like the rise of liquid biopsies, which enable non-invasive, next-gen sequencing, they highlight the potential for easier and safer tumor monitoring. Challenges like the limitations of analyzing small populations are addressed, emphasizing the value of large-scale, actionable databases in understanding diseases like breast cancer. They also discuss the future of molecular diagnostics in streamlining cancer prevention trials and the need to look beyond "gateway mutations" for a deeper understanding of dynamic cancer evolution. A key theme is the collaborative synergy between ConcertAI and Caris Life Sciences, emphasizing the goal of producing high-quality, meaningful data that can shape the future of oncological research and care. Interested in learning more about ConcertAI and Caris Life Science's joint offering? Download our factsheet today! Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

In this engaging episode, David Spetzler, President of Caris Life Sciences, and Jeff Elton, CEO of ConcertAI, discuss the transformative power of combining clinical insights and advanced AI technologies to revolutionize patient care in oncology. Highlighting their collaborative efforts, they emphasize the critical role of comprehensive data analysis, from leveraging longitudinal clinical records to employing next-generation sequencing for personalized treatment strategies. The conversation underscores a shared commitment to advancing medical science by accelerating the development and validation of new therapies, ultimately aiming to enhance patient outcomes through precision medicine. Through this partnership, they envision a future where diagnostics and targeted treatment strategies significantly extend human life years, demonstrating the profound impact of integrating cutting-edge technology and collaborative innovation in healthcare. Watch the live video interview here: https://vimeo.com/816357933/ab745bd0a1?share=copy Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

The second episode of The ConcertAI Podcast features Dr. Sibel Blau and Caroline Merillat, key figures in the Quality Cancer Care Alliance (QCCA) and creators of Exigent. This initiative aims to improve clinical research in community oncology, making trials more accessible and reflective of standard care populations. Dr. Blau, motivated by a dream to cure cancer, emphasized the importance of maintaining the independence of oncology practices for superior patient care. Merillat, with extensive experience in research, is dedicated to expanding trial access, especially for underserved populations. Exigent, by leveraging real-world data and collaborative efforts, seeks to enhance trial quality and speed, emphasizing a patient-centric approach that prioritizes the right trials for patients. This innovative model showcases the potential of community oncology to lead in research and patient care, underscoring the significance of independent practices in the healthcare ecosystem. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

In this captivating episode of The ConcertAI Podcast, we dive deep with Jennifer Rider, a renowned cancer epidemiologist. Jennifer shares her journey from academia to the dynamic world of real-world data (RWD) and its vital role in oncology research. We explore how RWD is transforming the landscape of prostate cancer studies and its increasing importance in regulatory decision-making. Discover how the field of RWD has evolved and its pivotal contributions to the development and application of groundbreaking oncology treatments. Jennifer's insights into the integration of RWD in clinical trials and its potential to shape future cancer therapies are truly enlightening. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

We're back with The ConcertAI Podcast for Season Two! In our first episodes, we delve deep into RWE's role in regulatory applications, such as designing registrational clinical trials and developing robust data sets that shape trial designs and submissions. We're exploring the evolving landscape of efficacy, safety, and the use of external control arms, especially in light of recent FDA guidance. But that's not all. Season Two also highlights incredible progress in clinical trial networks and technologies, especially those facilitating trials in community settings. We're excited to feature Exigent, a key partner in the development of ConcertAI's Digital Trial Solutions. Moreover, we're expanding our focus on multimodal data. From discussing its significance and new analytic approaches like AI and causal inference, to exploring real-world applications in study design and analyses. Expect deep dives into patient responses, patterns of resistance to treatments, and how these insights are revolutionizing study designs. Join us for insightful discussions, expert interviews, and a journey into the future of healthcare and clinical research. Listen to The ConcertAI Podcast on Apple Podcasts or Spotify, and immerse yourself in the latest innovations in healthcare technology. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

In this episode, we're thrilled to have Dr. Andy Beck, the Co-founder and CEO of PathAI, one of the leading digital pathology companies, as our guest. Digital pathology is transforming the accessibility of decision rules and decision augmentation, creating translational assets and changing how clinical development occurs. Dr. Beck shares insights on the progress and life of digital pathology, and how it's transforming healthcare. With the level of data and insights available to medical professionals, clinical interpretation will move far earlier, bringing a sense of optimism for cancer patients everywhere. Tune in to this episode to learn about the future of clinical development, and how AI-based models derived from digital pathology are creating a new paradigm in healthcare. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

A 2-Part Special with Bristol Myers Squibb on the Digitally Accelerated Clinical Trial (DACT) Model. In part 1, we will be joined by Marissa Co, Vice President of R&D Business Insights & Analytics, and Gaelan Ritter, Head of Analytics Innovation and Digital Health, who shed light on the exciting ways clinical trials are evolving and improving patient outcomes. The team at Bristol Myers Squibb will be discussing their groundbreaking work using the Digitally Accelerated Clinical Trial (DACT) model in the biopharma industry which leverages automation and integrates with various clinical data sources to collect more data and improve trial efficiency. This not only allows for more rapid completion of trials, but also facilitates the identification of eligible patients. Join us as we explore these exciting developments and learn how they are changing the biopharma landscape. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

In this episode, we continue to discuss the historic challenges of running clinical trials in community settings and how AI-powered patient identification tools and semi-automated data solutions are changing the game. Bristol Myers Squibb's Marisa and Gaelan share how their collaboration with ConcertAI on the Digitally Accelerated Clinical Trial Solution (DACT) is lowering the burden on patients and sites, and increasing the number of clinical trial types that can be run in community settings. The platform not only meets FDA imperatives but also makes much-needed medicines available to a wider array of patients. Join us as we dive deep into the exciting developments in clinical research and discover how technology is improving patient outcomes. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

ConcertAI is grateful to have a presence in a geography with such a fast pace of technical innovation, and is excited for the future. Tune in to the latest episode of The ConcertAI Podcast, hosted by CEO Jeff Elton! This week's episode explores the topic of globalizing healthcare and biopharma technical innovation. Jeff and Jitendra Gupta talks about what it really means to be a global company, and the amazing progress that India has made in advancing the healthcare and biopharma technology industry. Don't miss out on this insightful episode! Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

In this episode of the ConcertAI podcast, join our CEO Jeff Elton and Dan McSweeney, President of TeraRecon, ConcertAI's digital imaging solution, for an informative and engaging discussion. TeraRecon is a leading solution for three-dimensional radiological interpretation, but what makes them stand out is their novel approach of integrating AI directly into care delivery models. Jeff and Dan explore the unique position of TeraRecon in the healthcare workflow and how their neutrality sets them apart from other players in the space. They also discuss the potential of AI in radiology and how it can reduce variation in clinical outcomes while increasing productivity. Don't miss out on this exciting exchange about healthcare technology and innovation. Tune in now to join the conversation! Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

Don't miss out on the latest episode of The ConcertAI Podcast featuring Catherine Richards, ConcertAI's chief data officer! Join us as we dive into the state of the field of real world data, why it's transforming, and how research is now enabled because of it. Tune in to gain more understanding about data sets and analyses derived from real world data. Click the link to listen now! Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

On this episode of The ConcertAI Podcast, we're joined by SVP of Clinical Development Technologies, Luke Dunlap. Luke and Jeff discuss the experience and transformation about how clinical trials are being conducted with some of the newest technologies and the value that's being realized. Take a deeper dive into our end-to-end software platform, Digital Trial Solutions, is being used to conduct pharmaceutical studies at clinical research sites and how it is subsequently reducing patient burden. You'll also hear about ConcertAI's Clinical Trial Optimization software system and how it is improving the efficiency of clinical research protocols. Learn how we are transforming and accelerating biomedical innovations over the course of the next two to five years. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

On this episode we are joined by Dr. Warren Whyte. Dr. Whyte heads up ConcertAI’s health equity and trial diversity initiatives through the ERACE (Engaging Research to Achieve Cancer Care Equity) program . As a leader in this field, his work and the work of his team has influenced all of what ConcertAI brings to clients, customers, and biopharma partners. This includes the integration of SDOH with all of our datasets - a first-in-class for anybody in the RWD Industry. His work also influenced integrating health equity and trial diversity considerations into all of our technology solutions. There couldn't be a more important topic with a more influential individual in the field! Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

On our first episode, special guest Claudio D'Ambrosio covers the topic of multi-modal data in biomedical research. Multi-modal data can allow some of the deepest most advanced research questions to be answered. We start with the questions and then we bring together layers of different data, of different origin, that surround the patient in service of that particular question. This will change and transform how we develop and test hypothesis and will accelerate early phase trial activities. D'Ambrosio also touches on ConcertAI's value of partnering. Biomedical innovations is a team sport. It requires the inputs of multiple types of expertise. It’s in the dynamics operating as a single company or single entity that we can really transform the performance of research activities. Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai

The ConcertAI Podcast is a monthly podcast which brings together subject matter experts who take a deeper dive on topics of interest and relevance like real world data, real world evidence, clinical development technologies and patient facing solutions for clinical diagnosis. To learn more please visit us at www.ConcertAI.com Website www.ConcertAI.com LinkedIn www.linkedin.com/company/concertai/ Twitter www.twitter.com/concertai